PT  - JOURNAL ARTICLE
AU  - N Jestin-Guyon
AU  - E H Ouaalaya
AU  - A Bernady
AU  - E Berteaud
AU  - J Casteigt
AU  - L Falque
AU  - F Le Guillou
AU  - J Moinard
AU  - M Molimard
AU  - L Nguyen
AU  - C Nocent
AU  - A Ozier
AU  - M Staali
AU  - C Raherison-Semjen
TI  - Sex-related differences and FEV1 decline among COPD patients: the French Palomb cohort
AID  - 10.1183/13993003.congress-2022.4514
DP  - 2022 Sep 04
TA  - European Respiratory Journal
PG  - 4514
VI  - 60
IP  - suppl 66
4099  - http://erj.ersjournals.com/content/60/suppl_66/4514.short
4100  - http://erj.ersjournals.com/content/60/suppl_66/4514.full
SO  - Eur Respir J2022 Sep 04; 60
AB  - Background: Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of mortality worldwide and its prevalence among women increased in the past decade in developed countries mainly due to tobacco consumption and other risk factors. This study investigates sex-related differences of FEV1 decline in a real-life cohort.Methods: Prospective multi-centered study of COPD patients recruited between 2013 and 2022. Information collected at inclusion and visits: smoking status, symptoms, clinical characteristics, comorbidities. The evolution of FEV1 was analyzed in patients with 2 or more measures.Results: 3,228 patients were enrolled in the study. Women (36.5%) were younger, had lower BMI and were more current smokers than men patients (p<0.001). Regarding symptoms women had more dyspnea (p<0.009) and exacerbations (p<0.001). No sex differences were found for chest tightness and cough, except for more expectorations among men (p<0.004). For comorbidities men had more hypertension, ischemic heart disease, diabetes and less anxiety, depression, osteoporosis and asthma (p<0.001). Men had a lower predicted FEV1 (57.4%) than women (60.5%) (p<0.001) and a more severe COPD according to GOLD classification (p=0.005). No sex-related differences was observed for FEV1 decline.Conclusion: This study demonstrates differences on characteristics and some clinical aspects of women and men with COPD.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 4514.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).